3-(2,3,4-trifluorophenyl)propanol | 377084-06-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2,3,4-trifluorophenyl)propanol
• 英文别名: 3-(2,3,4-trifluorophenyl)-1-propanol；3-(2,3,4-Trifluorophenyl)propan-1-ol
• CAS: 377084-06-5
• 化学式: C₉H₉F₃O
• 分子量: 190.165
• InChiKey: QRWOSXAVHYZSTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  237.2±35.0 °C(Predicted)
• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2,3,4-trifluorophenyl)propanol 在 N-溴代丁二酰亚胺(NBS) 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-(3-溴丙基)-2,3,4-三氟苯
  参考文献：
  名称：

  AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  公开号：

  EP2168944B1
• 作为产物：
  描述：

  3-(2,3,4-trifluorophenyl)-2-propyne-1-ol 在 palladium-carbon 氢气 作用下， 以 1,4-二氧六环 为溶剂， 反应 9.0h， 以to give the object product (2.88 g) as a dark-green oil的产率得到3-(2,3,4-trifluorophenyl)propanol
  参考文献：
  名称：

  AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF

  摘要：

  提供的是一种新型胺类化合物，其化学式表示为(I)，具有优异的外周血淋巴细胞减少作用、免疫抑制作用、排异抑制作用等，表现出例如心动过缓等副作用减少的优点，或其药学上可接受的酸加盐，或其水合物，或其溶剂化物。 其中，每个符号如规范中所定义。

  公开号：

  US20100179216A1

文献信息

• Bicyclic cyclohexylamines and their use as nmda receptor antagonists
  申请人：——

  公开号：US20030236252A1

  公开（公告）日：2003-12-25

  Described are bicycle-substituted cyclohexylamines of Formula (I) and their pharmaceutically acceptable salts thereof. The compounds are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, cerebral ischemia, cardiac arrest, stroke, and Parkinson's specification. disease. The substituents are defined in the specification. 1

  描述了公式（I）的自行车替代环己胺及其药用盐。这些化合物是NMDA受体通道复合物的拮抗剂，可用于治疗脑血管疾病，例如脑缺血、心脏骤停、中风和帕金森病。这些取代基在规范中有定义。
• Amine compound and pharmaceutical use thereof
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：US08129361B2

  公开（公告）日：2012-03-06

  Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.

  提供的是一种新型胺类化合物，其化学式如下（I），具有卓越的外周血淋巴细胞降低作用和免疫抑制作用，抗排异作用等方面表现出降低副作用的优点，例如心动过缓等，或其药学上可接受的酸盐，或其水合物，或其溶剂化物。 其中，每个符号如规范中所定义。
• Cell-Permeable and Plasma-Stable Peptidomimetic Inhibitors of the Postsynaptic Density-95/<i>N</i>-Methyl-<scp>d</scp>-Aspartate Receptor Interaction
  作者：Anders Bach、Jonas N. N. Eildal、Nicolai Stuhr-Hansen、Rasmus Deeskamp、Marie Gottschalk、Søren W. Pedersen、Anders S. Kristensen、Kristian Strømgaard

  DOI：10.1021/jm1013924

  日期：2011.3.10

  The protein protein interaction between the NMDA receptor and its intracellular scaffolding protein, PSD-95, is a potential target for treating ischemic brain diseases, neuropathic pain, and Alzheimer's disease. We have previously demonstrated that N-alkylated tetrapeptides are potent inhibitors of this interaction, and here, this template is exploited for the development of blood plasma-stable and cell-permeable inhibitors. Initially, we explored both the amino acid sequence of the tetrapeptide and the nature of the N-alkyl groups, which consolidated N-cyclohexylethyl-ETAV (1) as the most potent and selective compound. Next, the amide moieties of N-methylated ETAV were systematically replaced with thioamides, demonstrating that one of three amide bonds could be :replaced without compromising the affinity. Subsequent optimization of the N-alkyl groups and evaluation of cell permeability led to identification of N-cyclohexylethyl-ETA(s)V (54) as the most potent, plasma-stable and cell-permeable inhibitor, which is a promising tool in unraveling the therapeutic potential of the PSD-95/NMDA receptor interaction.
• US8129361B2
  申请人：——

  公开号：US8129361B2

  公开（公告）日：2012-03-06
• AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2168944B1

  公开（公告）日：2016-05-11